Related Experiment Video
Updated: Sep 14, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Non-muscle invasive bladder cancer in a pregnant patient
Návan van Jaarsveld1, Jeff John1,2
1Division of Urology, Department of Surgery, Frere Hospital and Walter Sisulu University, East London, 5200, South Africa.
Malignant bladder tumors during pregnancy are exceedingly rare and account for less than 2.5 % of all malignancies. NMIBC presents unique diagnostic and management challenges, particularly in balancing maternal and fetal outcomes. We describe a 29-year-old woman diagnosed with NMIBC at 10 weeks' gestation, presenting with macroscopic hematuria. Ultrasonography and MRI confirmed the diagnosis, and TURBT revealed a high-grade T1 NMIBC. Post-operative surveillance and deferred intravesical therapy ensured maternal and fetal safety. The case underscores the challenges in balancing oncological and obstetric outcomes. While TURBT is safe during pregnancy, comprehensive follow-up and post-partum BCG are critical for long-term disease control.
Malignant bladder tumors during pregnancy are exceedingly rare and account for less than 2.5 % of all malignancies. NMIBC presents unique diagnostic and management challenges, particularly in balancing maternal and fetal outcomes. We describe a 29-year-old woman diagnosed with NMIBC at 10 weeks' gestation, presenting with macroscopic hematuria. Ultrasonography and MRI confirmed the diagnosis, and TURBT revealed a high-grade T1 NMIBC. Post-operative surveillance and deferred intravesical therapy ensured maternal and fetal safety. The case underscores the challenges in balancing oncological and obstetric outcomes. While TURBT is safe during pregnancy, comprehensive follow-up and post-partum BCG are critical for long-term disease control.
